Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 17.84% is 42% above its 5-year average of 12.58%, near the high end of its 5-year range (10.01%–19.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.41% above its 12-month average of 15.46%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 17.84%.
DEBT TO ASSETS RATIO
17.84%
DEBT TO ASSETS RATIO AVG TTM
15.46%
DEBT TO ASSETS RATIO AVG 3Y
13.36%
DEBT TO ASSETS RATIO AVG 5Y
12.58%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+15.41%
CURRENT VS 3Y AVG
+33.55%
CURRENT VS 5Y AVG
+41.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.29%
median of 98 covered companies
CURRENT VS SECTOR MEDIAN
+6160.47%
vs the sector median at left
Beam Therapeutics Inc.
Market Cap
$2.51B
Debt to Assets Ratio
17.84%
TTM Avg
15.46%
3Y Avg
13.36%
5Y Avg
12.58%
Market Cap
$2.74B
Debt to Assets Ratio
0.59%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.14B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.73B
Debt to Assets Ratio
0.44%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.72B
Debt to Assets Ratio
0.09%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.00B
Debt to Assets Ratio
0.38%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$397.55M
Debt to Assets Ratio
0.10%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | $2.51B | 17.84% | 15.46% | 13.36% | 12.58% |
| TransMedics Group, Inc. (TMDX)vs › | $2.74B | 0.59% | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.14B | 0.05% | N/A | N/A | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.73B | 0.44% | N/A | N/A | N/A |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.72B | 0.09% | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.00B | 0.38% | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $472.39M | 0.33% | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $459.30M | 0.66% | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $397.55M | 0.10% | N/A | N/A | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $41.03M | 0.50% | N/A | N/A | N/A |
Debt/Assets
17.8%
Debt/Equity
0.23
Current Ratio
14.57
Interest Coverage
-8.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 17.84% |
| 2026-03-31 | 16.94% |
| 2025-12-31 | 19.84% |
| 2025-09-30 | 11.55% |
| 2025-06-30 | 11.13% |
| 2025-03-31 | 10.78% |
| 2024-12-31 | 14.62% |
| 2024-09-30 | 13.84% |
| 2024-06-30 | 13.10% |
| 2024-03-31 | 12.36% |
| 2023-12-31 | 11.83% |
| 2023-09-30 | 13.37% |
| 2023-06-30 | 12.95% |
| 2023-03-31 | 13.24% |
| 2022-12-31 | 13.34% |
| 2022-09-30 | 12.95% |
| 2022-06-30 | 12.53% |
| 2022-03-31 | 10.33% |
| 2021-12-31 | 10.01% |
| 2021-09-30 | 12.58% |
| 2021-06-30 | 15.97% |
| 2021-03-31 | 19.70% |
| 2020-12-31 | 23.83% |
| 2020-09-30 | 12.34% |
| 2020-06-30 | 12.06% |
| 2020-03-31 | 11.08% |
| 2019-12-31 | 20.01% |
| 2019-09-30 | 13.72% |
| 2019-06-30 | 12.79% |
| 2018-12-31 | 0.00% |
